PepGen Inc (PEPG) USD0.0001

Sell:$1.50Buy:$1.65$0.15 (8.93%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.50
Buy:$1.65
Change:$0.15 (8.93%)
Market closed | Prices delayed by at least 15 minutes
Sell:$1.50
Buy:$1.65
Change:$0.15 (8.93%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Key people

James G. Mcarthur
President, Chief Executive Officer, Treasurer, Secretary, Director
Noel P. Donnelly
Chief Financial Officer
Paul D. Streck
Executive Vice President, Head of Research & Development (R&D)
Dave Borah
Senior Vice President - Investor Relations and Corporate Communications
Steve Han
Senior Vice President - Clinical Development
Afsaneh Mohebbi
Senior Vice President - Portfolio and Program Management
Hayley Parker
Senior Vice President - Global Regulatory Affairs
Niels Svenstrup
Senior Vice President - Chemistry, Manufacturing and Control
Mary Beth Delena
General Counsel, Company Secretary
Laurie Bartlett Keating
Independent Chairman of the Board
Mitchell Finer
Director
Lisa Wyman
Director
Habib Joseph Dable
Independent Director
Heidi Henson
Independent Director
Click to see more

Key facts

  • EPIC
    PEPG
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US7133171055
  • Market cap
    $52.63m
  • Employees
    81
  • Shares in issue
    32.69m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.